MedTrace Logo

Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)

NCT07148193 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1600

Last updated 2025-12-08

No results posted yet for this study

Summary

The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.

Conditions

  • Sarcoma
  • Survivorship
  • Quality of Life (QOL)
  • Medical Care

Interventions

OTHER

No intervention (observational study)

No intervention (observational study)

Sponsors & Collaborators

  • German Sarcoma Foundation (DSS)

    collaborator UNKNOWN

  • German Cancer Research Center

    collaborator OTHER

  • Universitätsmedizin Mannheim

    collaborator OTHER

  • University Hospital, Essen

    collaborator OTHER

  • National Centre for Tumor Diseases Heidelberg

    collaborator UNKNOWN

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Martin Eichler, Dr. · TU Dresden & NCT/ UCC Dresden

  • Karen Steindorf, Prof. Dr. · DKFZ Heidelberg

  • Richard F. Schlenk, Prof. Dr. · NCT Heidelberg

  • Jens Jakob, Prof. Dr. · Sarcoma Center Mannheim

  • Uta Dirksen, Prof. Dr. · University Hospital, Essen

  • Markus Wartenberg · Deutsche Sarkom-Stiftung

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-28
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07148193 on ClinicalTrials.gov